BMP Sunstone's Propess(R) Recommended as First Line Treatment By the Chinese Medical A...(areas of women's health and pediatrics. ...),Health

Safe Harbor Statement

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts, including educating healthcare providers and the future demand for Propess(R). These statements are subject to uncertainties and risks including, but not limited to, the ability to meet with healthcare providers and impact the acceptance of the product in the marketplace and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

BMP Sunstone Corporation:

Fred M. Powell

Chief Financial Officer

Tel: 610-940-1675

Integrated Corporate Relations, Inc.

In the U.S.:

Ashley Ammon MacFarlane and Christine Duan

Tel: 203-682-8200

In Asia:

Xuyang Zhang

Tel: +86-10-8523-3087